Supreme Court Asked to Halt Abortion Pill Dispensing Restrictions
Abortion pill makers have urged the Supreme Court to pause a ruling reinstating in-person dispensing.
Why it matters: The Supreme Court’s response will determine whether mifepristone, used in most U.S. pregnancy terminations, remains available by mail or returns to stricter in-person requirements. It directly impacts access to medication abortion and heightens the legal stakes for healthcare regulation and reproductive rights attorneys nationwide.
- On May 1, 2026, the 5th Circuit reinstated in-person dispensing for mifepristone.
- Danco Laboratories filed an emergency Supreme Court appeal on May 2, 2026.
- The FDA dropped the in-person requirement for mifepristone in 2021, allowing mail and telehealth access.
- Mifepristone is used in nearly two-thirds of U.S. pregnancy terminations.
Mifepristone manufacturers are appealing to the Supreme Court after the 5th Circuit reinstated rules requiring the abortion pill to be dispensed in person, rolling back access by mail.
- The May 1, 2026, 5th Circuit decision was prompted by a Louisiana lawsuit that challenged the FDA's 2021 relaxation of dispensing requirements for mifepristone.
- Previously, the FDA's policy allowed pregnant patients to receive the medication via telehealth and mail, a move intended to increase access, particularly during the pandemic.
- In an emergency application, Danco Laboratories said, "It bears emphasis how unprecedented the Fifth Circuit’s order is," and warned the ruling “injects immediate confusion and upheaval into highly time-sensitive medical decisions.”
Mifepristone plays a major role in reproductive healthcare, being used in nearly two-thirds of U.S. abortion procedures (Washington Post).
For attorneys advising healthcare providers or reproductive rights organizations, the Supreme Court’s response could reset the regulatory landscape for medication abortion nationwide.
Louisiana Attorney General Liz Murrill said, "I look forward to continuing to defend women and babies as this case continues."
By the numbers:
- 2/3 — Estimated share of U.S. pregnancy terminations using mifepristone
- 2000 — Year the FDA approved mifepristone
- 2021 — Year the FDA allowed mifepristone to be mailed to patients
What's next: The Supreme Court is expected to rule soon on Danco Laboratories' emergency appeal, which will guide nationwide mifepristone access during ongoing litigation.